Sankt Gallen
Sankt Gallen
Sankt Gallen, Canton of St. Gallen, Switzerland60 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT07100080 | |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) | Advanced Solid Tumors; Malignant Neoplam | Not yet recruiting | Phase 2 | 2026-10-08 | NCT07793942 | |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-10-07 | NCT05067283 | |
| Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) | cancer, neoplasm | Recruiting | Phase 1 | 2026-10-06 | NCT07600749 | |
| A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-10-06 | NCT06091254 | |
| A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Recruiting | Phase 3 | 2026-10-02 | NCT06430801 | |
| A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) | Lipoprotein(a) | Recruiting | Phase 2 | 2026-10-01 | NCT07614984 | |
| Clinical Outcomes of Rectopexy for Rectal Prolapse | Digestive System Diseases, Fecal Incontinence, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Prolapse, digestive system disorder, intestinal disorder, pelvic organ prolapse, rectal disorder, rectal prolapse | Active, not recruiting | Not stated | 2026-09-30 | NCT07848308 | |
| A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06052059 | |
| Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Not yet recruiting | Phase 2 | 2026-09-25 | NCT07840456 | |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06717347 | |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2026-09-25 | NCT03342144 | |
| Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, interstitial lung disease, lung disorder, respiratory system disorder, skin disorder, systemic sclerosis | Active, not recruiting | Phase 2 | 2026-09-22 | NCT05270668 | |
| Pharmacoscopy for Patients With Refractory Primary Brain Tumors | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, astrocytoma (excluding glioblastoma), central nervous system cancer, ependymoma, epithelial neoplasm, glioblastoma, glioma, medulloblastoma, meningioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor, tumor of meninges, vascular cancer | Recruiting | Phase 2 | 2026-09-21 | NCT06804655 | |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-15 | NCT06615479 | |
| Flow-Controlled Ventilation to Improve Postoperative Pulmonary Outcome After Thoracic Surgery | Mechanical Ventilation; Postoperative Pulmonary Complications (PPCs) | Not yet recruiting | Not applicable | 2026-09-08 | NCT07623395 | |
| A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 3 | 2026-09-02 | NCT06468228 | |
| AI Ambient Scribe in Psychiatry | Artificial Intelligence (AI); Burnout; Documentation; Efficiency of Physician Documentation; Empathy; Quality Improvement; Therapeutic Alliance | Active, not recruiting | Not applicable | 2026-08-20 | NCT07777224 | |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 3 | 2026-08-20 | NCT05889182 | |
| NEST: A Group Intervention for Parents With Complex PTSD | Complex Post-Traumatic Stress Disorder | Not yet recruiting | Not applicable | 2026-08-14 | NCT07766265 | |
| A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT04232553 | |
| Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | Adult Solid Tumor; Metastatic Non-Squamous Non-Small Cell Lung Cancer | Recruiting | Phase 2 | 2026-08-10 | NCT07098988 | |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-08-10 | NCT06926868 | |
| Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) | autosomal dominant Parkinson disease 4 | Active, not recruiting | Phase 1 | 2026-08-07 | NCT05853367 | |
| Underweight, Overweight, and Linear Growth of Childhood Cancer Patients - the Growth Study | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Thinness, childhood malignant neoplasm, neoplasm, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Not stated | 2026-08-06 | NCT07750444 |